Skip to main content
. Author manuscript; available in PMC: 2019 Nov 27.
Published in final edited form as: J Biopharm Stat. 2015;25(4):812–829. doi: 10.1080/10543406.2014.920858

Table 5.

Power (percent) for detecting a treatment effect based on 4000 simulations in a two-arm, two-treatment crossover study, by μ and the standard deviation of the values after treatment (σTrt). Results are for at least 99% of the simulations, except as indicated.

Model μ (16 per arm, σTrt = 1) μ (30 per arm, σTrt = 1.4)
2.0 2.5 3.0 4.0 2.0 2.5 3.0 4.0
Nonparametric analyses
Friedman test (NQ only) 56.8 64.9 68.4 69.3 28.4 50.6 64.2 75.0
Friedman test (both NQ and ND) 61.5 66.6 70.0 68.9 41.0 57.0 66.3 75.6
Schouten/Kester test 19.5 28.6 37.4 40.7 14.4 29.4 47.3 64.7
Mixed models using follow-up data only
Equal variances 68.9 78.4 84.6 87.1 30.5 58.4 76.8 89.9
Unequal variances 42.4a 70.5a 83.3 86.7 56.1a 77.2a 86.0 89.6a
Mixed models using both baseline and follow-up data
Equal variances 44.3 51.6 56.9 58.6 18.5 36.1 53.5 71.4
Unequal variances 36.8 49.4 56.3 58.6 31.5 49.8 63.5 73.2
Mixture models: likelihood L2, follow-up data only
Equal variances 14.1 17.0 17.0a NA NS NS NS NS
Generalized estimating equation logistic regression models for a significant decrease
NQ and ND combined 21.0 31.1 38.9 42.5 14.3 29.4 47.3 64.7
ND separate from NQ 30.4 36.4 42.0 43.0 24.3 40.0 53.6 65.8

Assumptions : treatment reduces the underlying mean μ by 0.5, the standard deviation of the untreated mean is 1, Type I error is 0.05, the quantification limit is log10(80) = 1.90. NQ: non-quantifiable; ND: not detectable.

NQ only : NQ and ND results were combined.

a

Results for 90% to 98.9% of all simulations

NA: Results for less than 20% of all simulations.

NS: not shown, excessive Type I error.